Cyclophosphamide, bortezomib and dexamethasone (CyBorD): a promising regimen for renal light chain deposit disease

环磷酰胺、硼替佐米和地塞米松(CyBorD):一种治疗肾轻链沉积病的有前景的方案

阅读:3

Abstract

Renal light chain deposit disease is a rare disease with rapid progression to renal failure when left untreated. There is no standard treatment available. We present a unique case of renal IgA kappa deposit disease who developed severe decline in renal function within a few months of diagnosis. She was started on a single regimen of cyclophosphamide, bortezomib and dexamethasone (CyBorD) followed by maintenance treatment with bortezomib and dexamethasone leading to rapid improvement of renal function. This is the first case to be reported on renal IgA kappa deposit disease who have responded dramatically to CyBorD without the need for any modification of the regimen or stem cell transplant.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。